Plaintiff seeks damages for Actos cancer

The plaintiff alleges that Takeda knew or should have known of the dangers associated with prolonged use of the drug, which is typically prescribed to treat type II diabetes, yet failed to take any action to warn the consuming public of risks associated with use of the drug. The plaintiff asserts that, due to the defective nature of Actos, he now suffers from bladder cancer, which has significantly impacted his lifestyle and quality of life.
He asserts that, had he known about the risks associated with the use of Actos, he would have never taken the drug and would have opted for a safer alternative.
According to the complaint, Actos is one of defendant Takeda Pharmaceuticals’ best-selling drugs, generating global sales of $4.8 billion in the last year, and is responsible for 27% of Takeda’s revenue.